What is the Jazz Pharmaceuticals plc stock price forecast?

Jazz Pharmaceuticals plc is currently trading at $230.56. View real-time AI analysis on Alpha Lenz.

What is Jazz Pharmaceuticals plc insider trading activity?

View the latest insider trading data for Jazz Pharmaceuticals plc on Alpha Lenz.

What is Jazz Pharmaceuticals plc's P/E ratio?

Jazz Pharmaceuticals plc's P/E ratio is -39.5.

Jazz Pharmaceuticals plc

NASDAQ · JAZZ

$230.56-5.61(-2.38%)Pre-market

Ask about Jazz Pharmaceuticals plc's future dividend policy...

Alpha Chat Insight

“Jazz Pharmaceuticals plc trades at a P/E of -39.5 (undervalued) with modest ROE of -8.5%.”

Ask for details →

Company Overview

Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.

CEOMs. Renee D. Gala

Websitehttps://www.jazzpharma.com

SectorHealthcare

IndustryBiotechnology

Employees2,800

Company Statistics

FY 2025

Profile

$14.06BMarket Cap

$4.27BRevenue

0.00Shares Out

2,800Employees

Margins

88.21%Gross

28.45%EBITDA

12.13%Operating

-14.71%Pre-Tax

-8.35%Net

Valuation

-39.48P/E

3.26P/B

3.29EV/Sales

14.90EV/EBITDA

12.27P/FCF

Growth (CAGR)

5.26%Rev 3Yr

12.54%Rev 5Yr

0.35%Op Inc 3Yr

-7.53%Op Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-3.01%ROA

-8.47%ROE

-3.66%ROIC

Financial Health

$1.39BCash & Cash Equivalents

$5.95BNet Debt

169.98%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Jazz Pharmaceuticals plc trades at a P/E of -39.5 (undervalued) with modest ROE of -8.5%.”

Ask for details →

Frequently Asked Questions

Jazz Pharmaceuticals plc (ticker: JAZZ) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 2,800 employees. Market cap is $14.1B.

The current price is $230.56 with a P/E ratio of -39.48x and P/B of 3.26x.

ROE is -8.47% and operating margin is 12.13%. Annual revenue is $4.3B.